Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: An analysis of immunological responses.
Authors
Yasuyoshi Sato
The Cancer Institute Hospital of JFCR, Tokyo, Japan
Yasuyoshi Sato, Koichi Yagi, Kazuhiko Mori, Hirokazu Matsushita, Kazuhiro Kakimi, Yasuyuki Seto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies
Sub Track
Cell Therapies
Clinical Trial Registration Number
UMIN000002837
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr 96)
DOI
10.1200/JCO.2018.36.5_suppl.96
Abstract #
96
Poster Bd #
F5
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand.
First Author: Nina Bhardwaj
Poster
2023 ASCO Annual Meeting
Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.
First Author: Sofie Kirial Mørk
Poster
2023 ASCO Annual Meeting
H3.3-K27M neoantigen vaccine elicits anti-tumor T cell immunity against diffuse intrinsic pontine glioma: The phase I ENACTING trial.
First Author: Yang Zhang
Poster
2023 ASCO Annual Meeting
Effect of personalized immunization with GNOS-PV02 of patients with hepatocellular carcinoma on TCR clonal expansion, tumor infiltration, and vaccine-specific reactivity.
First Author: Renzo Perales